ErbB-4 is a recently described member of the epidermal growth factor receptor (EGFR) family which together with erbB-3 acts as a receptor for a group of ligands known as the neuregulins (NRGs) or heregulins (HRGs). Unlike the EGFR and erbB-2 relatively little is known about the expression of erbB-4 in human tumours. Using RT ± PCR and Southern blotting analysis we have investigated the expression of erbB-4 mRNA in a range of human tumour cell lines and in normal and malignant breast tissue. Using primers which ampli®ed a 658 base pair (bp) region corresponding to part of the cytoplasmic domain of c-erbB-4 we found the receptor was expressed in some but not all breast and ovarian tumour cell lines and also in a glioma cell line. The highest level of erbB-4 expression was found in the ovarian carcinoma OVCAR-3 and the breast carcinoma T-47D. In all cell lines where the`full-length' erbB-4 was detected, a second previously undescribed c-erbB-4 sequence was also found as a 610 bp PCR product. The alternative PCR product was identical in sequence to c-erbB-4 except for a deletion of 48 bp which encodes a consensus phosphatidylinositol 3-kinase (PI3K) binding site. This suggested that the two forms of erbB-4 might interact with dierent intracellular signalling pathways and therefore in¯uence a wider variety of cellular responses to heregulin than previously thought. Expression of both erbB-4 variants was found in 7/7 normal breast tissues but only in 9/12 breast tumours analysed. In line with the terminology of Elenius et al. (1997b) we have designated the two isoforms of the Cterminal transcripts as CT-a (full-length) and CT-b which lacks the PI3K binding motif. These results identify suitable cell lines for the further investigation of erbB-4 expression and function and suggest that the role of erbB-4 in breast cancer warrants further investigation with larger numbers of normal and malignant breast tissues.
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Keywords: receptor tyrosine kinase; breast cancer; erbB-4; signal transduction; phosphatidylinositol 3-kinase ErbB-4, a transmembrane receptor tyrosine kinase, is a member of the epidermal growth factor receptor (EGFR) family which in addition to the EGFR includes erbB-2 (Coussens et al., 1985) and erbB-3 (Kraus et al., 1989) . Over-expression of the epidermal growth factor receptor and p185 erbB-2 has been reported in a wide variety of human malignancies (Modjtahedi and Dean, 1994; Hynes and Stern, 1994) and has been found to correlate with poor prognosis in patients bearing these tumours. Importantly, these molecules have been used as targets for the therapy of human disease (Baselga et al., 1996; Modjtahedi et al., 1996) . Relatively little is known about the expression of the recently discovered, related receptor, erbB-4 and its importance in human malignancy but a group of ligands, neuregulins, which bind to and activate this receptor have been described. The neuregulin family (NRG) includes the products of two alternately spliced genes NRG1 (Marchionni et al., 1993) and NRG2 (Chang et al., 1997; Carraway et al., 1997) and a third gene, NRG3 (Zhang et al., 1997) . The neuregulins bind to erbB-4 and erbB-3 and can stimulate phosphorylation of all four receptors via the formation of receptor heterodimers (Riese et al., 1995; Cohen et al., 1996b) . In addition, there is evidence that ligands thought initially to bind exclusively to the EGFR also bind to and activate erbB-4 including betacellulin (Riese et al., 1996) and HB-EGF (Elenius et al., 1997a) . The activated receptors interact with a variety of intracellular signalling pathways which can ultimately lead to either cell division or dierentiation. Clearly, it is important to determine the expression of p180 erbB-4 in cancer cells but preliminary experiments suggested that the level of expressed protein was low in many tumour cell lines. It was decided therefore to investigate initially erbB-4 expression by monitoring erbB-4 mRNA in human tumour cell lines most of which have been characterized previously in terms of their erbB-2 and EGFR expression. RT ± PCR is more sensitive than immunochemical techniques and by optimization of the number of PCR cycles the results obtained were semi-quantitative and re¯ected the dierential levels of mRNA present in the cell lines. Messenger RNA was isolated from 13 tumour cell lines of dierent origin (seven breast carcinoma, three ovarian, one glioma, one squamous cell carcinoma and one synovial cell carcinoma) then cDNAs were synthesized. PCR ampli®cation of cDNA using the erbB-4 speci®c primers, 253 and 256, resulted in the production of a 658 bp band in some cell lines which was the expected size for the product of erbB-4 ampli®cation ( Figure 1a, upper panel) . In addition, a second band was produced which was not anticipated and this appeared to be approximately 610 bp. Where the 658 bp product was observed then a 610 bp product was always present. The amount of the 658 bp PCR product varied and was absent from some cell lines: MDA-MB-468, CH1, SK-OV-3 and HN5. High levels of erbB-4 mRNA as shown by the presence of a 658 bp band were found in the cell lines T-47D and OVCAR-3, intermediate levels in BT-474, MCF-7, MDA-MB-453 and SK-BR-3 and low levels were found in MDA-MB-231, A-172 and A-2095. The relative levels of expression of the two messages varied between dierent cell lines. For example, the cell line T-47D expressed more of the larger message as shown by the greater intensity of the upper band (658 bp) in the doublet whereas OVCAR-3 appeared to express equivalent amounts of the two messages as shown by a b Figure 1 (a) RT ± PCR ampli®cation of erbB-4 (upper panel) and GAPDH (lower panel) from human tumour cell line mRNA and cDNA. (b) RT ± PCR ampli®cation of erbB-4 (upper panel) and GAPDH (lower panel) from malignant and from normal human breast tissue. Poly A+ mRNA was isolated from cultured cells using a QuickPrep Micro mRNA kit (Pharmacia Biotech, Uppsala) and the yield of RNA was determined in a GeneQuant (Pharmacia Biotech). Samples of human breast in®ltrating ductal carcinomas or normal tissues obtained from healthy women who had undergone reduction mammoplasties were collected and immediately snap-frozen in liquid nitrogen. Total RNA was prepared from tumour and normal tissues using the method of Chomcszinski and Sacchi (1987) . First strand cDNA was synthesized from either 5 mg total or 150 ng poly A+ mRNA using a pd(N) 6 primer (Pharmacia cDNA synthesis kit). Polymerase chain reactions were carried out in a total volume of 50 ml and contained 50 ng each of the forward and back primers, 1.5 mM MgCl 2 , 0.4 mM deoxynucleotide triphosphates (Pharmacia), 2 ml template cDNA and 2.5 U Taq polymerase (Life Technologies). For ampli®cation of erbB-4 cDNA with primers Back253 (5'-AAG GAT GGC TCG AGA CCC TCA-3') and For256 (5'-GGA CCA TTG GAT GCA TTG TGA TA-3'), the reaction mixtures were cycled 30 times (928C for 1.5 min; 508C for 1.5 min; 728C for 1.5 min) followed by incubation at 728C for 10 min. For ampli®cation of GAPDH cDNA with primers GAPDH and GAPDH1 (Stratagene) the reaction mixtures were heated at 948C for 5 min and 608C for 5 min then cycled 18 times (948C for 45 s; 608C for 45 s; 728C for 1.5 min) followed by a ®nal extension at 728C for 10 min. DNA fragments were separated by electrophoresis in 1.5% agarose gels and viewed using an ultraviolet transilluminator the similar intensity of both the 658 bp and 610 bp bands. In addition to the 658 and 610 bp PCR products there were other minor bands present in samples which had been ampli®ed with primers 253 and 256. For, example the predominant product of ampli®cation of HN5 and MDA-MB-468 cDNA was approximately 450 bp but this was found to be derived from EGFR mRNA which is overexpressed in these cells (Sawyer, 1997) . To compare the levels of expression of the dierent ampli®ed cDNAs a 600 bp region of the`house-keeping' gene glyceraldehyde 3-phosphate dehydrogenase (GAPDH) was ampli®ed from each of the cDNA samples. There appeared to be approximately equal amounts of ampli®ed GAPDH in all the cell lines as shown by equivalent intensity of most bands following analysis by agarose gel electrophoresis ( Figure 1a , lower panel). Any small dierences in the intensities of the bands were taken into account when estimating the relative levels of erbB-4 mRNA (Table 1) . Therefore, the large degree of variation observed in the levels of erbB-4 PCR product re¯ected real dierences in erbB-4 mRNA expression and were not the result of dierences in the quantity of RNA used for the cDNA synthesis.
We next investigated the level of erbB-4 mRNA in normal and malignant breast tissues. Again, erbB-4 was detected as a 658 bp PCR product in 9/12 in®ltrating ductal carcinomas of the breast and in 7/7 normal breast tissues (Figure 1b, upper panel) . This was an important ®nding because erbB-4 mRNA expression in normal or malignant human breast tissue has not been reported prior to this investigation. In common with the human tumour cell lines, a 610 bp product was also present whenever a 658 bp product was observed. The expression of erbB-4 RNA as shown by the presence of a 658 bp band varied between dierent tumour samples and between normal and tumour tissues. Relative expression levels are summarized in Table 2 . Unlike some of the cell lines, where there appeared to be greater expression of the larger message, there appeared to be some tissues which expressed higher levels of the smaller message as shown by the brighter intensity of the lower (610 bp) of the two bands. Three tumours, 27, 29 and 30, did not express any detectable erbB-4 mRNA whereas all normal tissues tested expressed erbB-4 message. Although the sample numbers were not large the dierence between the normal and malignant breast tissues may provide a clue as to a function of the erbB-4 receptor. GAPDH was expressed by all normal tissues and by 11/12 breast tumours (Figure 1b , lower panel), there was no detectable ampli®cation of GAPDH from tumour 27. The small variation in the amount of ampli®ed GAPDH product was taken into account when the relative erbB-4 expression levels were estimated (Table 2) .
Southern blot analysis was carried out to determine if the two products which resulted from the amplification of cell line and tissue cDNAs were derived from erbB-4 speci®c mRNA. Nested primers (C51 and C52), designed to hybridize to an erbB-4 PCR product just inside the region bound by primers 253 and 256 used for ampli®cation, were radiolabelled with 32 P and used simultaneously to probe Southern blots. The radiolabelled probes hybridized with the 658 bp band in the ampli®ed cell line cDNA samples con®rming that this band resulted from the ampli®cation of erbB-4 sequence (Figure 2a) . Unexpectedly, the labelled probes also bound strongly to the 610 bp PCR product which suggested that this band also resulted from the ampli®cation of erbB-4 and that a truncated erbB-4 transcript was expressed in these cell lines. The intensity of bands varied greatly between dierent samples con®rming the varying levels of erbB-4 mRNA expression in the cell lines. Hybridization to the 610 bp and 658 bp bands appeared to be equivalent except in the synovial cell carcinoma line A-2095 where there appeared to be greater hybridization to the 658 bp band. The increased sensitivity of the Southern blot revealed PCR products which were not visible on an ethidium bromide stained agarose gel. For example, there appeared to be a low level of 610 bp product from HN5 cDNA although no 658 bp product was detected. When ®lm was exposed to the blot for a T25  T27  T28  T29  T30  T77  T79  T81  T82  T83  T84  T85  N8  N10  N13  N15  N74  N75 
Tissue from which mRNA was prepared was either normal breast (N) or breast tumour (T);
b Relative level of erbB-4 RNA expression, taking into account the level of GAPDH PCR product (Column 2), was either high (H), intermediate (I), low (L) or undetected (7) ErbB-4 transcript expression in normal and malignant breast C Sawyer et al longer period of time (Figure 2a, lower panel) then weak hybridization was seen to 610 bp and 658 bp PCR products of MDA-MB-231 and SK-OV-3 cDNA ampli®cation. These cell lines were previously thought not to express erbB-4 mRNA because bands were not observed on gel analysis of RT ± PCR products. It became apparent that MDA-MB-231 and SK-OV-3 cell lines expressed a very low basal level of erbB-4 mRNA which was only detectable by the more sensitive technique of Southern blotting.
When Southern blots of the ampli®ed erbB-4 cDNAs from normal and malignant breast tissues were probed with radiolabelled primers C51 and C52 strong hybridization of the probes to 610 bp and 658 bp PCR products was again observed (Figure 2b) . In contrast to the Southern blot of the cell lines ( Figure  2a ) there was little variation in the intensity of the bands produced from ampli®cation of dierent tissue cDNAs but this could be due to changes in expression caused by the long-term culture of the cell lines. In addition, there was no obvious dierence in the level of erbB-4 expression between positive tumours and the normal breast tissues. However, there was variation in the extent of hybridization of the probe to the 610 bp and 658 bp PCR products which concurred with ®ndings from ethidium staining of the agarose gel that the proportions of these two messages varied between the samples. For example, normal breast tissues 75 and 76 and breast tumours 25 and 77 expressed relatively more of the truncated message whilst tumour 28 expressed relatively more of the`fulllength' message. Initial analysis of the RT ± PCR products by agarose gel electrophoresis suggested that breast cancers 27, 29 and 30 did not express erbB-4 RNA. However, extended exposure of the ®lm to the Southern blot (Figure 2b , lower panel) revealed that a band of 610 bp was present in these tumour samples which indicated low level expression of the truncated erbB-4 message.
To con®rm that the sequences of the 610 bp and 658 bp PCR products were derived from erbB-4, the PCR products from OVCAR-3 cDNA were cloned into the vector pCRII (Invitrogen Corporation, Leek, The Netherlands) and sequenced by the dideoxymediated chain termination method. The entire 658 bp PCR product was sequenced and found to be identical to the published sequence of c-erbB-4 from nucleotides 2958 to 3615. The sequence at each end of the 610 bp PCR product was also identical to that of c-erbB-4. However, there appeared to be a deletion of 48 nucleotides from the`full-length' erbB-4 transcript which had resulted in the production of the 610 bp PCR product. An additional alteration was that the triplet codon for asparagine (amino acid 1044) was AAC in the shorter transcript as opposed to AAT in the published c-erbB-4 sequence and in the sequence of the 658 bp PCR product (Figure 3 ). This dierence was not due to a sequencing error as it was found in both T7 and C51 primer sequenced DNA.
The deletion which resulted in the 610 base pair PCR product retained the reading frame of c-erbB-4 and would code for a protein which was 16 amino acids shorter than the full-length receptor, providing that no further deletions were present in the complete sequence of this new transcript. Within the 16 amino acids absent from the erbB-4-related protein is the sequence motif YTPM which forms a consensus phosphatidylinositol 3-kinase (PI3K) binding site (Cantley et al., 1991) . PI3K is a signalling intermediate which is known to interact with phosphorylated substrates such as the intracellular domain of tyrosine kinase receptors. The absence of a binding site for PI3K from the erbB-4-related receptor suggests that it is part of an alternative signalling pathway which may provide a dierent role for this novel receptor from that of the`full-length' erbB-4. This ®nding has not been reported by any other researchers. The signifia b Figure 2 Southern blot analysis of RT ± PCR products of erbB-4 ampli®cation of (a) cell line cDNA probed with erbB-4-speci®c nested primers and autoradiographed for 3 h (upper panel) or 24 h (lower panel) and (b) normal and malignant human breast tissue cDNAs autoradiographed for 1.5 h (upper panel) or 7 h (lower panel). For the probing of Southern blots oligonucleotides (50 ng/ml) were end-labelled with 5 ml [g 32 P]ATP (Redivue, A0018; Amersham) using 1 ml T4 polynucleotide kinase (Pharmacia Biotech). Samples of cDNA were electrophoresed in a 1.5% agarose gel then denatured by soaking the gel in 1.5 M NaCl, 0.5 M NaOH for 30 min and then neutralized by incubating in 3 M sodium acetate, pH 5.5 for 30 min. DNA was transferred by blotting onto Duralose-UV membrane (Stratagene) then crosslinked to the ®lter by exposure to UV light in a Stratalinker. The membrane was prehybridized at 508C in 20 ml QuickHyb solution (Stratagene) then labelled oligonucleotide probe (BackC51: 5'-AGA TAC CTA GTT ATT CAG GG-3' and ForC52: 5'-TTC GGG ATT ATC CAA TGC TT-3') and 200 ml sheared salmon sperm DNA (5 mg/ml stock) were added and the ®lter incubated for a further 90 min at 508C. After washing in 66SSC for 5 min at 408C and three times for 3 min at room temperature the ®lter was sealed in a polythene bag and exposed to autoradiograph ®lm at 7708C
ErbB-4 transcript expression in normal and malignant breast C Sawyer et al cance of the`short form' erbB-4 message is not known but the observation that its expression was retained by both normal and most malignant breast tissues and tumour cell lines suggests that it plays a functionally important role. It seems likely that the two erbB-4 variants have arisen through alternate splicing of the c-erbB-4 gene. The 48 nucleotide deletion could represent an intron with a cryptic splice site at its 5' end which is only used sometimes. The intron-exon structure of c-erbB-4 is not known but introns always start with the nucleotides GT (Breathnach et al., 1978) which are also found at the beginning of the 48 nucleotides missing from the shorter erbB-4 transcript. If phosphorylated tyrosine 1056 of the`full-length' erbB-4 protein was responsible for the binding of the p85 subunit of PI3K then the shorter receptor would not be able to interact with PI3K and would therefore signal via an alternative route. Interaction between p180 erbB-4 and the p85 subunit of PI3K has been reported by Sepp-Lorenzino and colleagues (1996) upon treatment of MDA-MB-453 breast cancer cells with heregulin-b2. Also, Cohen and colleagues (1996a) used peptide inhibition analysis to demonstrate that tyrosine 1056 of erbB-4 is responsible for binding PI3K. Furthermore, we have found that both the short and long isoforms of the receptor appear to be biologically active since they bind 125 I-heregulin-b1 when expressed in COS-7 cells and are phosphorylated on tyrosine residues (data not shown). Recently, Elenius et al. (1997b) have shown that erbB-4 is expressed as two dierent juxtamembrane isoforms that dier by the insertion of either 23 (JM-a) or 13 (JM-b) alternative amino acids. The dierent isoforms were expressed in a tissue speci®c manner and were activated by speci®c ligand. They suggest that the dierent isoforms represent cleavable (JM-a) or non cleavable (JM-b) forms of erbB-4. In the case of the two variants that we have cloned from T-47D cells (I. Hiles, unpublished) the extracellular domains were identical to the original published (JMa) form . To distinguish our two C-terminal isoforms from those of Elenius et al. (1997b) we have designated them CT-a for the fulllength erbB-4 and CT-b for the short form lacking the PI3K binding motif.
The CT-a transcript was observed in 9/13 cell lines as a 658 bp PCR product and the relative expression levels were similar to those found by Plowman et al. (1993) . T-47D cells were one of the highest expressors of erbB-4 mRNA, while MCF-7 cells expressed intermediate levels and MDA-MB-231 and MDA-MB-468 cells expressed low or undetectable levels of erbB-4 mRNA. More recently, others have also found similar levels of erbB4 mRNA expression in tumour cell lines and have used antibodies to con®rm that the level of protein expression correlates with the level of mRNA expression (Sepp-Lorenzino et al., 1996) . However, the RT ± PCR results described here dier from the RT ± PCR analysis published by Chan and co-workers (1995) who report that erbB-4 message levels were highest in SK-OV-3 cells and low or undetectable in MCF-7, SK-BR-3 and MDA-MB-453 cells. These dierences may be due to the use of dierent primers for the ampli®cation of the cDNA or dierences in cell culture techniques used by dierent laboratories for the growth of the same cell lines.
Full-length CT-a and short CT-b transcripts were also expressed in normal human mammary gland tissue and by human mammary adenocarcinomas. However, dierences were found between the tumour cell lines and the breast tumour tissues. There appeared to be less variation in the level of erbB-4 mRNA expression in the samples of breast tumour compared to the variation in the erbB-4 mRNA expression level in the tumour cell lines. This dierence is not easily explained but it could be important if, as suggested, the two forms of erbB-4 receptor activate dierent signalling pathways. A signi®cant ®nding from the RT ± PCR analysis of erbB-4 expression was that while all of the normal breast tissues examined expressed both erbB-4 variants three of the breast tumours expressed neither erbB-4 transcript. This was an important observation as tumour cells not only have an increased rate of proliferation over normal cells but may also become less dierentiated than their normal counterparts so that, for example, a breast tumour may not be histologically similar to the normal mammary gland surrounding it. Dierentiation is one of the events known to be triggered by the erbB-4 ligands, NRGs Yang et al., 1995; Bacus et al., 1996) and perhaps the loss of expression of erbB-4 in some breast tumours gives rise to an NRG-indepena b Figure 3 Partial nucleotide and predicted amino acid sequences of (a) 658 bp and (b) 610 bp erbB-4-related PCR products cloned from OVCAR-3 cells. PCR products were puri®ed using a`Gene Clean' kit (Bio101, La Jolla, CA, USA) and were cloned into the pCRII vector for sequencing using a TA Cloning Kit (Invitrogen). The ligation reactions were then used to transform competent E coli INVaF' cells by heat shock at 428C. Transformed cells were plated onto Luria-Bertani (LB) agar plates containing 100 mg/ml ampicillin and spread with 40 ml X-Gal (Sigma; 40 mg/ml stock in dimethylformamide) and incubated overnight at 378C. White colonies were picked into LB broth and grown with aeration at 378C overnight. Plasmid DNA was puri®ed from the bacterial cultures using the Tip-20 system (Qiagen, Dorking, Surrey) then sequenced manually by the dideoxy chain termination method (Sanger et al., 1977) using conventional heat denaturation (Andersen et al., 1992) and Sequenase 2.0 (USB, Cleveland, Ohio) dent state and a more aggressive tumour whilst normal mammary gland retains erbB-4 expression and the ability to respond to NRG-induced signals. This suggestion is based upon the analysis of a relatively small number of tissue samples but con¯icts with reports which describe heregulin as a tumour promoting factor (Holmes et al., 1992; Lupu et al., 1996) . It is important to follow up this study with the analysis of greater numbers of normal and malignant breast tissues.
In conclusion, the EGFR family of receptor tyrosine kinases is unusual in that one member, namely erbB-2, does not appear to directly bind a ligand while another member, erbB-3, binds the neuregulin family of ligands but appears to be devoid of catalytic activity. Epidermal growth factor and TGFa bind exclusively to the EGFR whilst the neuregulins have at least two receptors, namely erbB-3 and erbB-4. One of the NRG1 splice-variants, heregulin-b1, induces a number of dierent responses in cells bearing its receptors including mitogenesis (Holmes et al., 1992) and dierentiation (Marte et al., 1995; Peles et al., 1992) . The discovery of a novel C-terminal transcript of erbB-4 is interesting because of its implications for alternative signalling pathways activated by the neuregulins, i.e. pathways which do not involve PI3K. Although the precise functions of PI3K are unclear it has recently been proposed that PI3K can regulate the activation of Akt, a serine/threonine protein kinase and prevent cells from undergoing apoptosis (Franke et al., 1997) . In addition, erbB-3 and erbB-4 are the only members of the erbB family which can associate with PI3K and the ability of erbB-4 isoforms to dierentially regulate PI3K could be important in tumourigenesis.
